Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Free Cash Flow (2022 - 2025)

Bioregenx's Free Cash Flow history spans 4 years, with the latest figure at $66579.0 for Q4 2025.

  • Quarterly results put Free Cash Flow at $66579.0 for Q4 2025, up 686.03% from a year ago — trailing twelve months through Dec 2025 was $29915.0 (up 105.83% YoY), and the annual figure for FY2025 was $29915.0, up 105.83%.
  • Free Cash Flow for Q4 2025 was $66579.0 at Bioregenx, up from -$77564.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $66579.0 in Q4 2025 to a low of -$649161.0 in Q2 2023.
  • The 4-year median for Free Cash Flow is -$32153.0 (2022), against an average of -$128957.4.
  • The sharpest move saw Free Cash Flow crashed 5528.46% in 2023, then soared 686.03% in 2025.
  • Year by year, Free Cash Flow stood at -$4364.0 in 2022, then crashed by 5528.46% to -$245626.0 in 2023, then skyrocketed by 95.37% to -$11361.0 in 2024, then soared by 686.03% to $66579.0 in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at $66579.0, -$77564.0, and $3205.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.